Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_6035_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •About the Editor
- •Contents
- •Contributors
- •Abbreviations
- •Preface
- •1. Natural Products as Drug Candidates
- •1.1 Introduction
- •1.2 An array of natural products
- •1.2.1 Plant-derived natural products
- •1.2.2 Microbial natural products
- •1.3 Importance of analytical techniques
- •1.3.1 A glance at extraction techniques
- •1.3.2 Microbial culturing techniques
- •1.3.3 Outlook and perspectives in nanoparticles
- •1.4 Natural products as a guide in drug design and synthesis
- •1.5 Natural products as promising drug candidates
- •1.5.1 Antiviral drug candidates
- •1.5.2 Antiparasitic drug candidates
- •1.5.3 Neuroprotective agents
- •1.6 Conclusion
- •Keywords
- •References
- •2. Traditional Knowledge for Drug Discovery
- •2.1 Introduction
- •2.2 Databases on indian remedial flora, indigenous medicines, and phytochemicals
- •2.2.1 Cultural preservation
- •2.2.2 Sustainable practices
- •2.2.3 Biodiversity conservation
- •2.2.4 Health and medicine
- •2.2.5 Climate change adaptation
- •2.2.6 Interconnectedness and wisdom
- •2.3 History of traditional knowledge
- •2.3.1 Indigenous healing practices
- •2.3.2 Aboriginal dreamtime
- •2.3.3 Traditional agriculture
- •2.3.4 Traditional crafts
- •2.3.5 Indigenous cosmologies
- •2.3.6 Traditional music and dance
- •2.3.7 Traditional navigation
- •2.4 Traditional medicine in plant formulations
- •2.4.1 Ayurveda
- •2.4.2 Traditional chinese medicine
- •2.4.3 Indigenous healing practices
- •2.5 Drug discovery
- •2.6 Aspects of developing plant-based drugs
- •2.6.1 Selection criteria for plants
- •2.6.2 Plant material authentication
- •2.6.3 Extraction methods
- •2.6.4 Isolation and structure elucidation of bioactive components
- •2.6.5 Standardization of plant formulations
- •2.7 Conclusions
- •References
- •3. Herbal Healing: Plant-Based Natural Products
- •3.1 Introduction
- •3.2 Classification of secondary metabolites
- •3.2.1 Phenolic compounds
- •3.2.2 Terpenes
- •3.2.3 Alkaloids
- •3.3 History of natural products
- •3.4 Drug discovery from natural products
- •3.5 Drugs derived from the plants
- •3.6 Conclusions
- •Keywords
- •References
- •4. Natural Products with Antimicrobial Properties
- •4.1 Introduction
- •4.2 Plants as antimicrobial agents
- •4.3 Marine sources as antimicrobial agents
- •4.4 Antimicrobial products derived from microorganisms
- •4.5 Conclusions and future trends
- •Keywords
- •References
- •5. Natural Products with Immunomodulatory Properties
- •5.1 Introduction
- •5.2.1 Aloe vera (l.) burm.f. (family: asphodelaceae)
- •5.2.2 Andrographis paniculata (burm. f.) wall.ex.nees. (family: acanthaceae)
- •5.2.3 Acorus calamus l. (family: araceae)
- •5.2.4 Allium sativum l. (family: alliaceae)
- •5.2.5 Azadirachta indica a. juss. (family: meliaceae)
- •5.2.6 Argyreia speciosa (l.f.) sweet (family: convolvulaceae)
- •5.2.7 Bidens pilosa l. (family: asteraceae)
- •5.2.8 Baliospermum montanum (willd.) müll.arg. (family: euphorbiaceae)
- •5.2.9 Boerhaavia diffusa l. (family: nyctaginaceae)
- •5.2.10 Boswellia serrata roxb. excolebr. (family: burseraceae)
- •5.2.11 Camellia sinensis (l.) kuntze (family: theaaceae)
- •5.2.12 Capparis zeylanica l. (family: capparidaceae)
- •5.2.13 Calendula officinalis l. (family: asteraceae)
- •5.2.14 Chelidonium majus l. (family: papaveraceae)
- •5.2.15 Carica papaya l. (family: caricaceae)
- •5.2.26 Glycyrrhiza glabra l. (family: leguminosae)
- •5.2.27 Hypericum perforatum l. (family: hypericaceae)
- •5.2.28 Hippophae rhamnoides l. (family: elaeagnaceae)
- •5.2.29 Hydrastis canadensis l. (family: ranunculaceae)
- •5.2.30 Jatropha curcas l. (family: euphorbiaceae)
- •5.2.31 Mangifera indica l. (family: anacardiaceae)
- •5.2.32 Mollugo verticillata l. (family: molluginaceae)
- •5.2.33 Matricaria chamomilla l. (family: asteraceae)
- •5.2.34 Momordica charantia l. (family: cucurbitaceae)
- •5.2.35 Morinda citrifolia l. (family: rubiaceae)
- •5.2.36 Nigella sativa l. (family: ranunculaceae)
- •5.2.37 Nelumbo nucifera gaertn. (family: nymphaeceae)
- •5.2.38 Nerium oleander l. (family: apocynaceae)
- •5.2.39 Ocimum tenuiflorum l. (family: labiatae)
- •5.2.40 Premna tomentosa willd. (family: verbanaceae)
- •5.2.41 Plantago sp. (plantago major l. and plantago asiatica l.) (family: plantaginaceae)
- •5.2.42 Psoralea corylifolia l. (family: fabaceae)
- •5.2.43 Prunella vulgaris l. (family: lamiaceae)
- •5.2.44 Punica granatum l. (family: punicaceae)
- •5.2.45 Rhinacanthus nasutus (l.) kurz (family: acanthaceae)
- •5.2.46 Salvia officinalis l. (family: lamiaceae)
- •5.2.47 Tamarindus indica l. (family: leguminosae)
- •5.2.48 Tinospora cordifolia (willd.) miers (family: menispermaceae)
- •5.2.16 Centella asiatica (l.) urb. (family: umbelliferae)
- •5.2.17 Cichorium intybus l. (family: asteraceae)
- •5.2.18 Cryptolepis dubia (burm.f.) m.r. almeida (family: apocynaceae)
- •5.2.19 Citrus aurantiifolia (christm.) swingle (family: rutaceae)
- •5.2.20 Curcuma longa l. (family: zingiberaceae)
- •5.2.21 Desmodium gangeticum (l.) dc. (family: fabaceae)
- •5.2.22 Eclipta prostrata (l.) (family: asteraceae)
- •5.2.23 Phyllanthus emblica l. (family: euphorbiaceae)
- •5.2.24 Evolvulus alsinoides (l.) (family: convolvulaceae)
- •5.2.25 Ficus benghalensis l. (family: moraceae)
- •5.2.49 Terminalia chebula retz. (family: combretaceae)
- •5.2.51 Urtica dioica l. (family: urticaceae)
- •5.2.52 Withania somnifera (l.) dunal (cultivated var.) (family: solanaceae)
- •5.3 Traditional importance of research to society and researchers
- •5.4 Conclusion
- •Keywords
- •References
- •6. Natural Products with Anticancerous Properties
- •6.1 Introduction
- •6.2 Plant-derived anticancer compounds
- •6.2.1 Polyphenols
- •6.2.2 Flavanoids
- •6.2.3 Brassinosteroids
- •6.2.4 Vinca alkaloids
- •6.2.5 Taxanes
- •6.2.6 Campothecin derivatives
- •6.3 Microorganisms-based anticancer compounds
- •6.3.1 Primary metabolites
- •6.3.2 Secondary metabolites
- •6.4 Selected medicinal plants with anticancerous activities
- •6.4.1 Curcuma longa l.
- •6.4.2 Viscum album l.
- •6.4.3 Colchicum autumnale l.
- •6.4.4 Raphanus sativus l.
- •6.4.5 Tinospora cordifolia wild
- •6.4.6 Nigella sativa l.
- •6.5 Therapeutic enzymes
- •6.6 Future perspective
- •6.7 Conclusion
- •Keywords
- •References
- •7. Natural Products with Antiviral Properties
- •7.1 Introduction
- •7.2 Source of natural products with antiviral activity
- •7.3 Main components of natural products
- •7.3.1 Flavonoids
- •7.3.2 Polyphenols
- •7.3.3 Polysaccharides
- •7.3.4 Terpenoids
- •7.4 Mechanisms of action of natural compounds in viral infections
- •7.4.1 Direct antiviral effect
- •7.4.2 Anti-inflammatory effect in viral infections
- •7.4.3 Effect on autophagy process
- •7.6 Conclusions
- •Keywords
- •References
- •8. Approaches to Develop Drugs from Natural Products
- •8.1 Introduction
- •8.2 Scenario of drug discovery
- •8.3 Efficient drug discovery engines
- •8.4 Drug discovery approaches using plants
- •8.4.1 Plant selection for screening purpose
- •8.4.2 Authentication of plants
- •8.4.3 Types of molecular markers
- •8.5.1 Parallel approach
- •8.5.2 Sequential approach
- •8.6 Structure elucidation of isolated compounds
- •8.7 Biological screening of extracts/fraction/isolates
- •8.7.1 Cell culture-based assay
- •8.7.2 Dialysis
- •8.7.3 Microdialysis
- •8.7.4 Ultrafiltration
- •8.7.5 Chromatography
- •8.7.6 Ligand fishing
- •8.8 Limitations
- •8.9 Molecular modelling and np database
- •8.10 Future thrust
- •8.11 Conclusion
- •Keywords
- •References
- •9. Strategies for Isolation and Identification of Bioactive Molecules from Natural Sources
- •9.1 Introduction
- •9.2 Bioactive compounds in natural sources and their pharmacological properties
- •9.3.1 Selection of materials
- •9.3.3 Types and properties of solvent for extraction
- •9.4 Extraction methods (conventional and modern)
- •9.4.1 Conventional methods
- •9.4.2 Novel extraction methods
- •9.5 Concentration and purification of bioactive molecules using chromatographic techniques
- •9.5.1 Separation based on adsorption properties
- •9.5.2 Separation based on partition coefficient
- •9.5.3 Separation based on the molecular size
- •9.5.4 Separation based on ionic strength
- •9.5.5 Other modern separation techniques
- •9.6 Identification and characterization of bioactive molecules
- •9.6.1 Qualitative and quantitative techniques/chromatographic or nonchromatographic techniques
- •9.7 Conclusions
- •Keywords
- •References
- •10. Role of Omics in Natural Product-Based Drug Discovery
- •10.1 Introduction
- •10.2 Genomics and transcriptomics in natural product discovery
- •10.2.1 Case studies and examples of natural product discovery using genomics and transcriptomics
- •10.2.2 Limitations and challenges of using genomics and transcriptomics in natural product discovery
- •10.3 Proteomics and metabolomics in natural product discovery
- •10.3.1 Case studies and examples of natural product discovery using proteomics and metabolomics
- •10.4 Bioinformatics in natural product-based drug discovery
- •10.4.1 Role of bioinformatics in natural product-based drug discovery
- •10.4.2 The use of bioinformatics to predict and annotate natural product biosynthetic pathways, gene clusters, and metabolomics
- •10.7 Future perspectives and potential impact of omics in natural product-based drug discovery
- •10.9 Potential impact on drug discovery and development
- •10.10 Conclusion
- •Keywords
- •References
- •11. Natural Products from Endophytic Microorganisms
- •11.1 Introduction
- •11.1.1 Rational/why endophytes?
- •11.2 Diversity of endophytic microorganisms
- •11.2.1 Endophytic bacteria and endophytic actinomycetes
- •11.2.2 Endophytic fungi
- •11.3.1 ISolation methods
- •11.3.1.1.1 Dilution Plating
- •11.3.1.1.2 Direct Plating
- •11.3.2 Identification methods
- •11.4 Bioactive compounds from endophytic microorganisms
- •11.4.1 Antibiotics
- •11.4.2 Antifungal agents
- •11.4.3 Antimalarial agents
- •11.4.4 Antiviral agents
- •11.4.5 Anticancer agents
- •11.4.6 Antioxidants
- •11.5 Stepwise methods for natural product discovery from endophytic microorganisms
- •11.5.1 Plant selection rationale
- •11.5.2 Isolation and cultivation of endophytes
- •11.5.3 Characterization of endophytes
- •11.5.4 Extraction of natural products
- •11.5.5 Purification of natural products
- •11.6 Biosynthesis and strategies for the optimization of natural product discovery from endophytic microorganisms
- •11.6.1 Exploration of novel microbial sources
- •11.6.2 Metabolomics-guided discovery
- •11.6.3 Coculture
- •11.6.4 Genome mining
- •11.6.5 Modulation by ultraviolent irradiation
- •11.7 Future directions and challenges
- •11.7.1 Improving the efficiency and accuracy of screening methods
- •11.7.2 Enhancing the scalability and affordability of production methods
- •11.7.3 Ensure natural product safety and efficacy
- •11.8 Conclusions
- •References
- •12. Natural Products with Antidiabetic Properties
- •12.1 Introduction
- •12.2 Natural products that regulate glucose absorption
- •12.2.1 Serotonin-derived products
- •12.2.2 Butyl-isobutyl-phthalate from laminaria japonica
- •12.2.3 Bioactive compounds of allium cepa and allium sativum
- •12.2.4 Elatosides E and F of aralia elata
- •12.2.5 Bioactive compounds of bauhinia candicans and bauhinia forficate
- •12.3 Natural products that enhance insulin sensitivity
- •12.3.1 Astragalus membranaceus polysaccharides
- •12.3.2 Bioactive compounds of litchi chinensis
- •12.3.3 Bioactive compounds of fenugreek
- •12.3.4 Bioactive compounds of cinnamon
- •12.3.5 Bioactive compounds of gastrodia elata
- •12.3.6 Polysaccharides of dioscorea
- •12.3.7 Anthocyanins of blueberries
- •12.3.8 Bioactive compounds of psidium guajava
- •12.4.1 Gingerol from zingiber officinale
- •12.4.2 Curcumin from curcuma longa
- •12.4.3 Berberine
- •12.4.4 Capsaicin of pepper
- •12.4.5 Bioactive compounds of bitter melon
- •12.4.6 Ginsenosides of ginseng
- •12.4.7 Bioactive compounds of aloe vera
- •12.4.8 Quinides of coffee
- •12.4.9 Bioactive compounds of tinospora cordifolia
- •12.4.10 Bioactive compounds of pterocarpus marsupium
- •12.4.11 Eugenol of ocimum sanctum
- •12.4.12 Bioactive compounds of syzygium densiflorum
- •12.5 Clinical trials based on antidiabetic effects of natural products derived from plants
- •12.5.1 Gymnema sylvestre (gurmar)
- •12.5.2 Fenugreek (trigonella foenum-graecum)
- •12.5.3 Tea catechins
- •12.5.4 Coffee
- •12.5.5 Rosemary (rosmarinus officinalis)
- •12.6 Conclusion
- •12.7 Future scope
- •Keywords
- •References
- •13. Marine-Derived Natural Products with Anticancer Properties
- •13.1 Introduction
- •13.2 Marine bioactive compounds
- •13.3 Anticancer activity of marine plants
- •13.4 Anticancer agents from marine floras
- •13.5.1 Antioxidants
- •13.5.2 Immunomodulation and apoptosis
- •13.5.3 Nutritional values and anticancer effects
- •13.6 Nature and cancer chemotherapy
- •13.7 Marine organisms and cancer chemotherapy
- •13.8 Anticancer agents from marine floras
- •13.9 Marine plants
- •13.9.1 Macro algae (seaweed)
- •13.9.2 Mangroves and other higher plants
- •13.9.3 Cyanobacteria
- •13.9.4 Bacteria
- •13.9.5 Proteobacteria
- •13.9.6 Cyanobacteria
- •13.9.7 Actinomycetes
- •13.9.8 Marine fungi
- •13.9.9 Soft corals
- •13.9.10 Marine sponges
- •13.10 Anticancer bioactive antibiotics derived from marine sources
- •13.10.1 Polyphenols
- •13.10.2 Polysaccharides
- •13.10.3 Alkaloids
- •13.11 Other marine sources for anticancer compounds
- •13.11.1 Peptides
- •13.11.2 Plitidepsin
- •13.11.3 Trabectedin
- •13.11.4 Lurbinectedin
- •13.12 Marine natural products as anticancer drugs
- •13.13.1 Aquaculture/cultivation
- •13.13.2 Genetic engineering
- •13.13.3 Synthesis/semisynthesis/modification
- •13.14 Conclusions and future prospects
- •References
- •14. Natural Products as Novel Opportunities for Cathepsin Inhibitors
- •14.1 Introduction
- •14.2 Cysteine proteases (CPs)
- •14.2.1 Cathepsin
- •14.2.2 Structure and mechanism of action of cathepsins
- •14.3 NPs as cathepsins inhibitors
- •14.3.1 NPs From bacteria as cathepsin inhibitors
- •14.3.2 NPs from fungus as cathepsin inhibitors
- •14.3.3 NPs from marine organism as cathepsin inhibitors
- •14.3.4 NPs from plants as cathepsin inhibitors
- •14.4 Conclusion and future pespectives
- •Keywords
- •References
- •15. Phytoestrogens in Drug Discovery: A Focus on Mechanisms of Action and Safety Assessment
- •15.1 Introduction
- •15.2 Phytoestrogens and estrogen receptors
- •15.3 Nonestrogen receptor-mediated effects of phytoestrogens
- •15.3.1 Mitogen-activated protein kinase (MAPK) pathway
- •15.3.2 PI3K/AKT pathway
- •15.3.3 WNT pathway
- •15.3.4 G-protein-coupled estrogen receptor (GPER)
- •15.4 Structure–activity relationship (SAR) of phytoestrogens
- •15.4.1 Isoflavones
- •15.4.2 Lignans
- •15.4.3 Coumestans
- •15.4.4 Stilbenes
- •15.4.5 Diarylheptanoids
- •15.5 Comparing potency and efficacy of phytoestrogens on various pathways
- •15.5.1 Potency and efficacy of phytoestrogens on different pathways
- •15.5.2 Possible synergistic effects of phytoestrogens with other drugs
- •15.6 Effects of phytoestrogens on the human organs
- •15.7 Safety Assessment of phytoestrogens
- •15.7.1 Toxicity assays used to evaluate the safety of phytoestrogens
- •15.7.2 Potential adverse effects of phytoestrogens
- •15.8 Case study
- •15.8.1 Vaginal cellular differentiation assay
- •15.8.2 Changes in rat body weight
- •15.8.3 Changes in rats’ uterus weight
- •15.9 Current trends in phytoestrogen research
- •15.9.1 Publication trends
- •15.9.2 Analysis of contributing countries and contributing institutions
- •15.9.3 Analysis of contributing publishers and journals
- •15.9.4 Publication evolution and research areas
- •15.9.5 Limitations
- •15.10 Future directions
- •15.10.1 Exploration of unexplored plant sources
- •15.10.2 Understanding mechanisms of action
- •15.10.3 Synthesis of novel compounds
- •15.10.4 Development of SPERMs
- •15.10.5 Safety assessment
- •15.11 Conclusion
- •Keywords
- •References
- •16. Honey Bee Products with Antimicrobial Properties
- •16.1 Introduction
- •16.2 Honey
- •16.3 Bee bread (perga)
- •16.4 Bee pollen
- •16.5 Bee propolis
- •16.6 Conclusion
- •Keywords
- •References
- •17. Natural Products for the Prevention of Leaky Gut
- •17.1 Introduction
- •17.2 The physical and chemical barriers of the intestine
- •17.2.1 Thick mucus layer
- •17.2.2 Intestinal epithelial cells (IECS)
- •17.2.3 Intestinal junctional complexes
- •17.2.4 Lamina propria
- •17.2.5 Intestinal regulatory T cells
- •17.2.6 Intestinal alkaline phosphatase
- •17.2.7 Antimicrobial peptides
- •17.2.8 Lysozyme
- •17.3 Mechanistic view of factors leading to a leaky gut
- •17.3.1 Gut dysbiosis
- •17.3.2 Mucosal inflammation and oxidative stress
- •17.3.3 TJ disruption
- •17.3.4 Genetics
- •17.3.5 Drugs
- •17.4 Pathological implications of a leaky gut
- •17.5 Natural product improving gut microbial dysbiosis
- •17.5.1 Traditional herbs and polyherbal formulations managing gut micro flora
- •17.5.2 Phytocompounds in the management of intestinal barrier integrity through balancing gut microflora
- •17.6.1 Anti-inflammatory traditional medicine and plant extracts ameliorating intestinal mucosal injury
- •17.6.2 Plant active constituents preventing mucosal injury and oxidative damage
- •17.7 Traditional medicine and natural products upregulating the TJ proteins
- •17.7.1 Traditional medicine and herbal extracts promoting junction protein protection
- •17.7.2 Phytocompounds for junction protein protection
- •17.8 Natural products averting pathological conditions through maintaining intestinal barrier function
- •17.9 Conclusion
- •Keywords
- •References
- •18. Role of Natural Products in the Pharmacotherapy of Osteoporosis
- •18.1 Introduction
- •18.1.1 Effect of traditional chinese medicine (TCM)
- •18.1.2 Effect of malay traditional medicine
- •18.1.3 Antiosteoporotic agents extracted from plant sources
- •18.1.4 Treatment by different pigments
- •18.1.5 Other herbal sources
- •18.1.6 Natural plant-based alkaloids
- •18.1.7 Essential markers involved in bone formation and resorption for osteoporosis treatment
- •18.2 Conclusion
- •Keywords
- •References
- •19. Gel-Based Natural Therapeutics: Potential Alternatives to Traditional Drug Delivery Systems in Aquaculture
- •19.1 INtroduction
- •19.2 DDS
- •19.2.1 Water medication
- •19.3 Oral administration
- •19.3.1 Gavage

333
Prior research has documented that chrysophanol functions as an inhibitor of the
epidermal growth factor receptor/mammalian target of rapamycin pathway, displaying
anticancer and anti-inammatory properties (Lee et al., 2011).
FIGURE 14.16 Polyketides penicitrinol G (41), penicitrinol H (42), chrysophanol (43), and (2,11-dihydroxy-
1-methoxycarbonyl-9-carboxylxanthone (44) isolated from fungus Penicillium citrinum.
⏎
14.3.4 NPS FROM PLANTS AS CATHEPSIN INHIBITORS
Several natural compounds isolated from various plants have demonstrated many interesting inhibitory activities against cathepsins. The first inhibitor was a member of the
cystatin superfamily (Brzin et al., 1998). They were phytocystatin isolated from extract
of red kidney bean (Phaseolus vulgaris L.). Phytocystatins are potent inhibitors of CPs
produced by plants, forming strong and stable complexes with them. Phytocystatin was
found to be a potent inhibitor of human Caths B, H, and L, with Ki values 3.6, 2.8, and
0.02 nM, respectively.
In their study , W isutsitthiwong et al. (201 1) explored the potential of 7-oxo-7-deacetoxygedunin (7-OG), a limonoid of the gedunin type (Figure 14.17) derived from the seeds of
the mangrove Xylocarpus moluccensis, as a potent inhibitor of osteoclastogenesis. Notably ,
7-OG exhibited robust anti-osteoclastogenic activity with minimal cytotoxicity toward the
monocyte/macrophage progenitor cell line, displaying an IC50 of 4.14 μM. Treatment with
7-OG led to the complete suppression of Cath K mRNA expression. In-vitro experiments
demonstrated that 7-OG effectively inhibited RANKL-induced osteoclast differentiation.
These suppressive effects on osteoclast formation can be attributed, at least in part, to 7-OG’ s
ability to inhibit the NF-κB and MAPK pathways. Furthermore, the anti-osteoclastogenic
activity of 7-OG is mediated, in part, by the suppression of NF-κB and MAPK pathways.
Investigation of downstream target genes revealed a complete downregulation of NFATc1

334
and Cath K. Additionally, treatment with this limonoid inhibited RANKL-induced activa-
tion of p38, MAPK, and Erk, as well as the nuclear localization of NF-κB. Taken together,
these ndings strongly suggest that 7-OG treatment interferes with osteoclast differentiation
at early stages following RANKL stimulation (Wisutsitthiwong et al., 2011). Limonoids
hold promise as potential therapeutic agents for osteoclast-related disorders.
FIGURE 14.17 Chemical structure of limonoid 7-oxo-7-deacetoxygedunin (45) isolated from Xylocarpus
moluccensis.
⏎
Dihydrochalcone and prenylated avone were identied from the bud of Artocarpus
altilis (Patil et al., 2002). Traditionally in Taiwan, the buds have been reported to possess
anti-inammatory and detoxifying effects (Chen et al., 1993). All the compounds
extracted from A. altilis demonstrated signicant inhibition activity against Cath K covers
(Figure 14.18). Compound (46) showed an IC50 value of 170 nM followed by compound
(47) with an IC50 value of 98 nM. Compound (48) was moderated inhibitor of Cath K with
IC50 values of 840 nΜ, respectively.
Biavones have been found to be potent inhibitors of Cath B and Cath K through
random screening, with some degree of selectivity for Cath B. Biavone compounds
were isolated and identied from acetone extracts of leaves and branches of Taxodium
mucronatum (Taxodiaceae) (49)–(51) and from methanol extracts of leaves of Cycas
guizhouensis (Cycadaceae) (52)–(54) (Figure 14.19). Zeng et al. (2006) demonstrated
that biavones are a novel class of cathepsin inhibitors from plants and exhibit a greater
degree of endopeptidase activity specically against Cath B. The kcat/Km value at pH 7.4
is much higher than that at pH 5.5, which means that, in weak neutral conditions, Cath B
can hydrolyze the endopeptidase substrate Z-FR-AMC more efciently. The pH preference
of Cath B against the substrate Z-FR-AMC was investigated in a pH-dependent prole at
pH 7.4 compared to pH 5.5. IC50 results indicated that under weak neutral conditions, the
inhibitory activities of biavones are slightly more potent than those under acidic conditions.
At pH 5.5, the IC50 range was 0.81–1.17 µM, and at pH 7.4, the IC50 range was 0.23–0.68
µM. These biavones are reversible Cath B inhibitors, according to inhibition and exible

335
docking experiments. The way these compounds bind and interact with Cath B makes them
effective inhibitors. According to the study, the new natural biavone inhibitors against
Cath B could open new strategies for developing innovative procedures for designing,
creating, and screening inhibitors of Cath B (Pan et al., 2005; Kassem et al., 2004).
FIGURE 14.18 Chemical structures of dihydrochalcone (46)–(47) and prenylated flavones (48) isolated
from Artocarpus altilis.
FIGURE 14.19 Chemical structures of biflavones isolated from Taxodium mucronatum (49)–(51) and Cycas
guizhouensis (52)–(54).
⏎
⏎
The Brazilian Cerrado biome is situated in the Central Brazilian highlands, encom-
2
passing approximately 2 million km
, which accounts for 23% of Brazil’s total land area.

336
It ranks as the second-largest vegetation formation on the South American continent,
trailing only the Amazon rainforest (Ratter et al., 1997). Known for its high biodiversity,
the Brazilian Cerrado is among the most diverse tropical savannas globally and represents
an arid ecosystem inhabited by native species adapted to its seasonally variable climate.
These woodland savannas are characterized by sparse canopies with scattered trees and
shrubs, some of which are endemic to the region. The Cerrado’s remarkable environmental
diversity positions it as one of the most biodiverse among all tropical savannas (Klink and
Machado, 2005). The Cerrado is an important and rich source of plants with unstudied
medicinal properties (Pinheiro and Monteiro, 2010). Ramalho et al. (2015) investigated
15 crude extracts from seven different Cerrado plants for the initial screening (125 µg/
mL). The most signicant inhibitory activity was observed in the ethanolic leaf extract of
Myrcia lingua Berg (Myrtaceae). The inhibition was higher than 90% against Caths L and B.
Bioactivity-guided fractionation resulted in the isolation of seven active polyhydroxylated
avonoids with and without glycosides (55)–(62) (Figure 14.20). The compounds showed
slightly more potency against Cath B. The most active compounds were (59) and (60) with
IC50 values of 4.9 and 8.2 µM, respectively. Polyhydroxylated avonols were shown to
be uncompetitive inhibitors against Cath B. Additionally, other avonoids isolated from
Esenbeckia grandiora Mart. (Rutaceae), Vochysia thyrsoidea Pohl. (Vochysiaceae), and
Byrsonima coccolo bifolia Kunth. (Malpighiaceae) were also evaluated for their inhibitory
activity against Cath B but did not show signicant inhibition at a concentration of 100 µM.
FIGURE 14.20 Chemical structures of polyhydroxylated flavonols (55)–(62) from Myrcia lingua Berg.
⏎
Rhizoma Drynariae (DR), usually named “Gol-Se-Bo” in Korean and “Gu-Sui-Bu”
in Chinese folk medicine, is one of the most frequently used herbs in traditional medicine for treating bone-related diseases. The biological effects of DR on in-vitro bone cell
culture, assessment of Cath K processing in bone cells, and examination of DR’s antibone
resorption activity have been investigated by analyzing inhibitory enzymatic activity
(Jeong et al., 2003). Dioscin (DR) demonstrates the potential to affect bone cell culture
without inducing cytotoxicity. The most efcacious concentration of DR for bone cells was
determined to be 100 µg/mL. When osteoclasts and osteoblasts, both types of bone cells,
were exposed to the PI3-kinase inhibitor wortmannin (WT), it resulted in the inhibition of
intracellular Cath K maturation. Likewise, the application of DR extracts to osteoclasts
containing long bone cells prevented the intracellular maturation of Cath K, indicating

337
that DR may impede the intracellular trafcking of pro-Cath K. The researchers conducted
experiments with WT and DR in the presence or absence of the mannose-6-phosphate
(M6P) receptor. Inhibition of Cath K in in-vitro bone resorption processing by both WT
and DR was observed in a dose-dependent manner, with similar potency observed for the
inhibition of Cath K processing.
The compounds Kushennol F (63) and Sohoravanone G (64) were isolated and identi-
ed from DR (Qiu et al., 2016) (Figure 14.21). Molecular docking and dynamics methods
showed that both compounds interact with Cath K. These compounds exhibited inhibitory
effects on the bone resorption process associated with Cath K. Biological studies were
conducted to verify the effects of these compounds on Cath K and its related bone resorption
process. Kushennol F (63) and Sohoravanone G (64) exhibited inhibitory activity against
Cath K, with IC50 values of 8.80 and 27.24 µM, respectively. The biological actions of KF
and SG on pit formation by osteoclasts were further conrmed using cultured RANKL-
induced osteoclastogenesis cells. The results clearly indicated that Kushennol F (63) and
Sohoravanone G (64) strongly suppressed osteoclastogenesis and inhibited Cath K-related
bone resorption. Signicantly, these two naturally derived compounds from plants have
displayed promising potential as novel inhibitors of Cath K, making them valuable for
potential applications in osteoporosis management.
FIGURE 14.21 Chemical structures of Kushennol F (63) and Sohoravanone G (64) isolated from DR.
⏎
The hexane and ethyl acetate (EtOAc) extracts of the stems of Bowdichia virgilioides
Kunth (Fabaceae) were assayed against Caths K, L, and V at a concentration of 125 µg/mL.
The extract with lower polarity (hexane) exhibited noteworthy inhibition against Caths L and
V, showing inhibitions of 91% and 97%, respectively . Similarly, the EtOAc extract displayed
inhibitory effects on Caths K, L, and V, with inhibitions of 70%, 97%, and 99%, respectively.
Bioassay-guided fractionation of the hexane and EtOAc extracts allowed the characterization
of lupeol, lupenone, β-sitosterol, and stigmasterol in mixture, a trans-p-coumaric acid ester
derivative, syringaresinol, bowdenol, 8-methoxycoumestrol, 3,4-hydroxy-7-methoxyisoavone, 7,3′-dihydroxy-4′-methoxyisoavone, and 5,4′-dihydroxy-7′-methoxyisoavone.

338
All isolated compounds were tested at an initial concentration of 50 µg/mL against Caths K,
L, and V. The most potent compounds were the trans-p-coumaric acid ester derivative (65)
and 8-methoxycoumestrol (65) (Figure 14.22). The derivative of trans-p-coumaric acid (65)
displayed 78% inhibitory activity on Cath L, 94% inhibition on Cath V, and 49% inhibition
on Cath K. Likewise, 8-methoxycoumestrol (66) showed 55% inhibitory activity on Cath
L, 78% inhibition on Cath V, and 35% inhibition on Cath K. Similarly, the EtOAc fraction
from B. virgilioides containing similar phenolic compounds (8-methoxycoumestrol and
isoavones) showed inhibition on Cath K, L, and V of 70%, 97%, and 99%, respectively, at
a concentration of 125 µg/mL. The enzyme inhibitory activity of 8-methoxycoumestrol (67)
was determined for Cath V, showing an IC50 value of 17.4 µM (Silva et al., 2019).
FIGURE 14.22 Chemical structures of trans-p-coumaric acid ester derivative (65) and 8-methoxycoumestrol
(66) isolated from Bowdichia virgilioides Kunth.
⏎
Similarly, chalcone derivatives (67–70) were extracted from the ethanol extract of
the inner bark of Myracrodruon Urundeuva Allemão and individually assessed for their
inhibitory activity against Cath V (Sarria et al., 2018) (Figure 14.23). Compound (67)
exhibited the highest inhibitory potency, with an IC50 value of 0.42 μM. Additionally,
compounds (66) and (68) displayed signicant inhibition, with IC50 values of 0.7 and 1.4
μM, respectively. In contrast, compound (69) exhibited only moderate inhibition, with an
IC50 value of 24 μM. Notably, this marks the rst instance of dimeric chalcones being
identied as inhibitors of Cath V.
Natural polycyclic polyprenylated benzophenones (71)–(73) were isolated from
Garcinia brasiliensis (Martins et al., 2009) (Figure 14.24). Guttiferone A (71) showed
inhibition against Cath G, with an IC50 value of 2.7 µM, which is quite similar to the classical inhibitor chymostatin (2.1 µM) for this peptidase. Inhibition on Cath B was observed
at 2.1 µM. The presence of both the bicycle[3.3.1]-nonanetrione and 13,14-dihydroxy
substituted phenyl groups, as well as the keto-enol tautomeric form where the bridge
carbon is hydroxylated, enhances the inhibitory activity of the enzyme. The derivatives of
polyisoprenylated benzophenones that contain the bicycle[3.3.1]-nonanetrione moiety have
been shown to inhibit DNA topoisomerases and telomerase, as well as act as regulators in
mitogen-activated protein (MAP) kinase signal transduction pathways. The bicycle[3.3.1]nonanetrione is useful for antineoplastic therapy by decreasing the activity of MAP kinases
during mitosis in cancerous and tumoral tissues.

339
FIGURE 14.23 Chemical structures of chalcone derivatives (67)–(70) isolated from Myracrodruon urundeuva
Allemão.
FIGURE 14.24 Chemical structures of polycyclic polyprenylated benzophenones (71)–(73) isolated from
Garcinia brasiliensis.
⏎
⏎
A compound library consisting of 270 chemical structures, including 111 NPs isolated
from Brazilian plants, was investigated through high-throughput screening to identify new

340
potent inhibitors of Caths K, V, L, and S (Severino et al., 2011). This study evaluated
a series of different classes of secondary metabolites, including alkaloids, coumarins,
triterpenes, cinnamic acids, amides, lignans, avonoids, and limonoids. The most promising results against the cathepsins were obtained for alkaloid and avonoid derivatives.
Severino et al. (2011) described the rst study in the literature to use NPs as reversible and
competitive inhibitors of Cath V. A series of acridone alkaloids (75)–(86) isolated from the
methanol extract of the stem bark of Swinglea glutinosa showed potent inhibitory activity
(Figure 14.25). The alkaloids were found to be reversible and competitive inhibitors of
Cath V . Acridone (80) was the most effective inhibitor with an IC50 value of 1.2 µM and Ki
of 200 nM. The inhibitor interacts with the enzyme’s amino acids through hydrogen bonds
and van der Waals interactions. The predicted conformation within the binding pocket of
Cath V revealed that the inhibitor interacts via four hydrogen bonds. First, the 1-hydroxyl
substituent acts as a hydrogen bond donor to the main-chain carbonyl group of Gly23 at
the S1 pocket. Second, the oxygen atom of the 2-methoxy substituent accepts a hydrogen
bond from the NH2 side-chain of Gln19, which forms part of the oxyanion hole in Cath V.
Third, the 5-hydroxyl substituent binds to the S2 pocket, acting as a hydrogen bond donor
to the main-chain carbonyl group of Leu157. Finally , the 9-carbonyl group binds to the S3
pocket by accepting a hydrogen bond from the NH main-chain of Gly66. In addition to
these polar contacts, nonpolar interactions also contribute to the orientation of the inhibitor
in Cath V. The side-chains of Phe67 and Cys25 form van der Waals interactions with the
1-hydroxyl and 2,3,4-trimethoxy substituted rings, respectively. The SAR data conrms
that the inhibitory activity is improved by the presence of polar substituents at R1 (2-position) and less bulky groups at R4 (8-position).
Considering the signicant challenge of nding selective cathepsin inhibitors, a
complementary database for a small series of acridone alkaloids (74)–(84) was evaluated
against Cath L (Marques et al., 2016). The compounds showed signicant inhibition of
Cath L, with IC50 values ranging from 0.8 to 57 μM. Alkaloids (74), (75), and (80) were the
most potent in the series, with IC50 values of 0.9, 0.8, and 1.5 μM, respectively. For Cath V,
the IC50 values ranged from 1.2 to 48.0 μM, with compounds (76), (79), and (80) being the
most potent, with IC50 values of 2.2, 2.2, and 1.2 μM, respectively. The selectivity observed
in this small series was low, suggesting that these inhibitors are not capable of selectively
inhibiting Caths L and V. However, important information from the SAR data could be
visualized. The comparison of compounds (74) and (76) shows that the potency of these
compounds is not affected by the presence of the prenyl substituent group at C-8 in ring A.
Similarly, the same is observed when comparing compounds (74) and (75) in terms of the
presence of a methoxy group at C-4. Analyzing compounds (76) and (77), it was observed
that the inclusion of the prenyl group at C-4 of ring B leads to a signicant decrease in
potency by a factor of approximately 12 times. On the other hand, the absence of the prenyl
group at C-2 of ring B in compound (77) suggests that this group is crucial for establishing
afnity with these cathepsins. The intramolecular cyclization of the prenyl group (80), (82),
(83), and (84) signicantly reduces the potency of the compounds compared to prenylated
alkaloids (74), (75), (76), and (77), suggesting that the formation of a fourth ring hinders
the interaction of the inhibitor with the catalytic site. The data suggest that the acridone
alkaloids are satisfactorily positioned in the region of the enzyme’s catalytic site, allowing

341
for important intermolecular interactions for molecular recognition. The aromatic rings A
and B can favor hydrophobic and van der Waals interactions, although this effect is less
pronounced in the case of tetracyclic compounds that hinder the planarity of the molecule
and, consequently, the hydrophobic interaction. Acridone alkaloids represent a potential
lead candidate for future medicinal chemistry, serving as new competitive inhibitors with
improved potency and afnity against Caths V and L.
FIGURE 14.25 Chemical structures of a series of acridone alkaloids (74)–(84) isolated from Swinglea glutinosa.
Triterpenoids have been identied as a new class of competitive inhibitors against
Cath L. Ramalho et al. (2014) have screened several natural triterpenes isolated from
plants (Figure 14.26). Three natural triterpenes, namely, 3-O-acetylursolic acid (85),
ursolic acid (86), and 3-epiursolic acid (87), were extracted from the stems of Myrcia
lingua Berg (Myrtaceae). 3-Oxoursolic acid (88) was identied from the stem bark of
Vochysia thyrsoidea (Vochysiaceae). Masticadienoic acid (89) and schinol (90) were
isolated from the fruit of Schinus terebinthifolius (Anacardiaceae). Interesting, the
⏎

342
evaluated triterpenoids did not show signicant inhibition on Cath B (IC50 ˃ 250 µM).
Molecular docking studies and analysis of the binding patterns and interaction modes on
Cath B revealed that due the size and rigidity of the triterpenoid ring systems, they cannot
pass through the narrow V-shaped channel in the enzyme’s active site. Consequently, the
structure is unable to interact with the amino acids in subsites S2 and S3, which are
crucial for the inhibitory activity. On the other hand, triterpenoids were active against
Cath L. The most promising was 3-epiursolic acid (87) with IC50 values of 6.5 μM on
Cath L. 3-O-acetylursolic acid (85) and ursolic acid (86) showed signicant inhibition on
Cath L with IC50 value of 12.3 and 39.5 µM. The moderate inhibitory activity exhibited by
triterpenoids against Cath L suggests their potential to greatly assist in the development
of new inhibitors with increased potency against this enzyme (Ramalho et al., 2014).
FIGURE 14.26 Chemical structures of triterpenoids (85)–(90) isolated from different plants.
⏎
The dipeptide asperphenamate (91) was isolated from raw malt, a traditional medicine
used for the treatment of mammary gland hyperplasia (Ling et al., 2005) (Figure 14.27).
Asperphenamate (91) can inhibit the proliferation of cancer cells and showed cell death
through the induction of autophagy (Yuan et al., 2012). The inhibition of cathepsin by
asperphenamate (91) against Caths L, S, K, and B was evaluated, showing a moderate
inhibitory effect on Caths L and S with IC50 values of 91.23 and 171.11 µM, respectively
(Li et al., 2021; Yuan et al., 2018).
EBOV and Marburg virus (MARV) are members of the Filoviridae family, known for
causing severe hemorrhagic fevers in both humans and nonhuman primates, often with
mortality rates as high as 90%. In a study conducted by Cui et al. (2018), researchers
prepared 373 extracts from plants commonly used in traditional Chinese herbal medicine
Соседние файлы в папке Библиотека им академика М.И. Перельмана
